1,950 Shares in Natera, Inc. $NTRA Bought by Prudential PLC

Key Points

• Prudential PLC has acquired a new stake in Natera, Inc., purchasing 1,950 shares valued at approximately $276,000 during the first quarter of the year.
• Wall Street analysts have mixed views on Natera, with one brokerage issuing a "sell" rating while others, including Royal Bank of Canada and UBS Group, providing "buy" ratings and raising their price targets for the stock.
• Natera recently reported quarterly earnings with a revenue of $546.6 million, significantly surpassing estimates, but posted a loss of ($0.74) per share, missing the expected ($0.60).

Prudential PLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,950 shares of the medical research company's stock, valued at approximately $276,000.

Other institutional investors also recently modified their holdings of the company. LRI Investments LLC acquired a new position in shares of Natera during the 4th quarter worth about $29,000. Bank of Jackson Hole Trust acquired a new position in shares of Natera during the 1st quarter worth about $29,000. Rakuten Securities Inc. increased its stake in shares of Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after purchasing an additional 119 shares during the last quarter. ORG Partners LLC acquired a new position in shares of Natera during the 1st quarter worth about $32,000. Finally, TCTC Holdings LLC grew its stake in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after buying an additional 124 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $157.07, for a total transaction of $471,210.00. Following the completion of the transaction, the insider owned 133,205 shares of the company's stock, valued at approximately $20,922,509.35. This trade represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 3,045 shares of Natera stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer directly owned 65,430 shares of the company's stock, valued at $8,990,082. This represents a 4.45% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,792 shares of company stock worth $9,227,972 over the last ninety days. Insiders own 5.63% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on NTRA shares. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research report on Monday, July 28th. Barclays restated an "overweight" rating and set a $210.00 target price (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Stephens restated an "overweight" rating and set a $183.00 target price on shares of Natera in a research report on Friday, August 15th. Finally, UBS Group increased their target price on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $193.19.

Natera Stock Performance

Shares of NASDAQ NTRA traded up $1.8040 during trading hours on Thursday, hitting $162.4440. 479,850 shares of the stock were exchanged, compared to its average volume of 1,516,017. The company has a market cap of $22.30 billion, a PE ratio of -85.03 and a beta of 1.76. The company's fifty day simple moving average is $154.89 and its two-hundred day simple moving average is $154.48. Natera, Inc. has a 1-year low of $110.57 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. Natera's revenue for the quarter was up 32.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.